Recently, a new class of therapeutics that disable the neonatal Fc receptor (FcRn), which protects IgG from degradation, has emerged to treat IgG-mediated autoimmune disease. 4,5 Here, we review ...

One of the primary mechanisms of SCFA benefits was the direct activation of a group of G-protein-coupled receptors (GPCRs), termed free fatty acid receptors (FFARs), the FFAR2 (GPR43), and FFAR3 ...

receptor agonist, which was being investigated for chronic weight management. Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731 ...